CytRx Posts Higher Q3 Net Loss on Increased R&D Spending
CytRx reported this week a rise in its third-quarter net loss to $2.9 million, from $2.5 million in the year-ago quarter, largely as a result of an almost 125 percent increase in research and development spending to $1.5 million.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
